SECOND ANNOUNCEMENT - Comtecgroup · exclusive forum for international experts to share and compare experiences, ... inaugural event of many future editions. ... Sweden A. Falanga,

The Academy for Clinical Debates & Controversies in Medicine

COHEMThe 1st World Congress on

Controversies in Hematology

[email protected] • www.comtecmed.com/cohemA comprehensive Congress fully devoted to clinical debates and controversial issues in the field of Hematology

ROME • ITALY • SEPTEMBER 2-5, 2010

AND CALL FOR ABSTRACTS

ANNOUNCEMENTSECOND

2

Over the years, the field of Hematology has undergone enormous expansion in clinicaltrials and basic research as well as in cutting-edge technology.

The 1st World Congress on Controversies in Hematology (COHEM) will function as anexclusive forum for international experts to share and compare experiences, in orderto outline the right treatment for patients.

The concept of this Congress stems from the fact that current congresses fail to promotetrue clinical discussion between practicing physicians and researchers on unresolvedpressing issues.

Participants will have the advantage of discussing and debating these unresolvedissues with leading world experts in all fields of Hematology. Allowing ample time forspeaker-audience discussion, the Congress aims at reaching up-to-date and agreed-upon answers to ongoing debates even when proof is lacking, through evidence-basedmedicine and expert opinion.

We invite you to take part in the 1st COHEM Congress which is intended as theinaugural event of many future editions.

We look forward to an exciting event in the beautiful city of Rome.

Prof. E. Rachmilewitz & Prof. G. SaglioCo-Chairpersons

On behalf of the Organizing Committee

Dear Friends and Colleagues,

ROME • ITALY • SEPTEMBER 2-5, 2010The 1st World Congress on Controversies in Hematology

3


E. Rachmilewitz, Israel • G. Saglio, Italy

Chairpersons

M. Baccarani, ItalyM. Björkholm, SwedenA. Falanga, ItalyJ. Goldman, UK

H. Kantarjian, USAM.M. Samama, FranceJ.F. San-Miguel, SpainC. Schiffer, USA

S. Amadori, Italy • R. Foà, Italy • R. Hehlmann, Germany • A. Nagler, Israel

Organizing Committee

Scientific Committee

Faculty

S. Amadori, ItalyW. Arcese, ItalyM. Attal, FranceM. Baccarani, ItalyA. Bacigalupo, ItalyT. Barbui, ItalyB. Barlogie, USAV. Berdoukas, GreeceM. Björkholm, SwedenM. Boccadoro, ItalyA. Burnett, UKC. Buske, GermanyJ. Bussel, USAF. Caligaris-Cappio, ItalyM.D. Cappellini, ItalyM. Cazzola, ItalyP. Corradini, ItalyB. de Pauw, The NetherlandsV. Diehl, GermanyP. Donnelly, The NetherlandsA. Falanga, ItalyR. Foà, ItalyG. Gaidano, ItalyN. Gattermann, GermanyF. Giles, USAC. Gisselbrecht, France

B. Godeau, FranceJ. Goldman, UKA. Goldstone, UKD. Grimwade, UKF. Guilhot, FranceA. Hagenbeek, The NetherlandsR. Hehlmann, GermanyA. Hochhaus, GermanyD. Hoelzer, GermanyM. Hutchings, DenmarkA. Kakkar, UKH. Kantarjian, USAG. Kontoghiorghes, CyprusN. Kröger, GermanyG. Leone, ItalyA. Levis, ItalyF. Lo-Coco, ItalyB. Löwenberg, The NetherlandsL. Luzzatto, ItalyJ. Maciejewski, USAF. Mahon, FranceJ.P. Marie, FranceD. Marin, UKM. Martelli, ItalyG. Marti, USAF. Menichetti, Italy

A. Nagler, IsraelO. Ottmann, GermanyA. Palumbo, ItalyM. Pfreundschuh, GermanyU. Platzbecker, GermanyA. Polliack, IsraelC. Portlock, USAA. Prentice, UKE. Rachmilewitz, IsraelK. Rai, USAA. Rambaldi, ItalyJ. Ribera, SpainS. Rivella, USAG. Saglio, ItalyM.M. Samama, FranceJ.F. San-Miguel, SpainV. Santini, ItalyM.A. Sanz, SpainC. Schiffer, USAD. Straus, USAC. Tarella, ItalyA. Tefferi, USAE. Terpos, GreeceW. Vainchenker, FranceA.M. Vannucchi, ItalyU. Vitolo, Italy

4


Preliminary Scientific Program

FRIDAY, SEPTEMBER 3, 2010

08:30-10:00 PLENARY SESSION 1 Hall A

Did we substantially improve MDS therapy in the last decade?Moderator: E. RachmilewitzYes: H. KantarjianNo: C. Schiffer

Is there a role for SCT in Multiple Myeloma?Moderator: N. KrögerYes: B. BarlogieNo: M. Boccadoro

10:30-12:30 SESSION 2 Hall A

ACUTE MYELOID LEUKEMIA (AML) I

About targeted therapies in AML: Have standard treatments reached their limits?Moderator: S. AmadoriYes: A. BurnettNo: B. Löwenberg

Should the therapy of AML be driven by MRD quantification?Moderator: B. LöwenbergYes: S. AmadoriNo: C. Schiffer


ACUTE MYELOID LEUKEMIA (AML) II andACUTE PROMYELOCYTIC LEUKEMIA (APL)

Do we require chemotherapy to cure APL?Moderator: A. BurnettYes: M.A. SanzNo: F. Lo-Coco

Can novel prognostic markers predict for success and guide therapy in AML?Moderator: C. SchifferYes: D. GrimwadeNo: A. Burnett


ACUTE LYMPHATIC LEUKEMIA (ALL)

Is the efficacy of the pediatric-like protocols for ALL superior to the protocols foradult ALL?Moderator: R. FoàYes: J.P. MarieNo: J. Ribera

Should the induction for Ph+ ALL be based on TKI alone or TKI plus chemotherapy?Moderator: J.P. MarieTKI Alone: R. FoàTKI plus chemotherapy: O. Ottmann

5



FRIDAY, SEPTEMBER 3, 2010

10:30-12:30 SESSION 5 Hall B

CHRONIC LYMPHATIC LEUKEMIA (CLL)

Is eradication of MRD feasible and worthwhile in CLL?Moderator: K. RaiYes: G. MartiNo: G. Gaidano

Is the “wait and watch” philosophy still practical in the treatment of CLL even in younger patients?Moderator: A. PolliackYes: K. RaiNo: F. Caligaris-Cappio


INDOLENT NON-HODGKIN’S LYMPHOMAS (NHL)

Is there a role for Rituximab in maintenance treatment in non-follicular indolentlymphomas?Moderator: C. PortlockYes: A. HagenbeekNo: C. Buske

Is molecular remission the goal in first line therapy of all patients with indolentnon-Hodgkin lymphoma?Moderator: A. HagenbeekYes: P. CorradiniNo: C. Tarella


MULTIPLE MYELOMA (MM)

Multiple Myeloma in patients <70 years: cure vs. disease controlModerator: M. BoccadoroCure: J.F. San-MiguelControl: A. Palumbo

Should Therapy for newly diagnosed MM be risk adapted?Moderator: A. PalumboYes: M. AttalNo: E. Terpos

6



SATURDAY, SEPTEMBER 4, 2010


STEM CELL TRANSPLANATION (SCT) IThe role of Allogeneic SCT (AlloSCT) in Hematological Malignancies

How should we treat a 60 year old patient with Myelodysplastic syndrome?Moderator: M. MartelliAlloSCT: N. KrögerConventional Therapy: U. Platzbecker

Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients?Moderator: W. ArceseAll: A. GoldstoneOnly high risk: D. Hoelzer


STEM CELL TRANSPLANATION (SCT) IIAlternative Donor and Reduced Intensity Conditioning (RIC) AlloSCT

Should CBT, Haploidentical transplant or MUD transplant be considered upfrontif no sibling donor is available?Moderator: A. RambaldiCBT: W. ArceseHaplo: M. MartelliMUD: A. Bacigalupo

Should we use AlloSCT in Acute Myeloid Leukemia RIC or Myeloablative preparative protocols?Moderator: A. BacigalupoRIC: A. NaglerMyeloablative: A. Rambaldi


MDS

Do hypomethylating agents improve survival in patients with high risk myelodysplastic syndromes?Moderator: G. LeoneYes: V. SantiniNo: M. Cazzola

Is there a rationale for iron chelation therapy in MDS?Moderator: E. RachmilewitzYes: N. GattermannNo: A. Tefferi

7





HODGKIN AND NON-HODGKIN LYMPHOMAS

Has PET/CT an established role in the management of HD and NHLs?Moderator: M. BjörkholmYes: M. HutchingsNo: U. Vitolo

Does molecular outcome prediction in DLBCL add clinical value?Moderator: M. BjörkholmYes: C. GisselbrechtNo: M. Pfreundschuh

8





CHRONIC MYELOID LEUKEMIA (CML) I

Will second generation TKIs substitute imatinib as first line treatment of CML?Moderator: R. HehlmannYes: M. BaccaraniNo: H. Kantarjian

Can we eventually stop TKI in all CML patients?Moderator: M. BaccaraniYes: F. MahonNo: J. Goldman


CHRONIC MYELOID LEUKEMIA (CML) II

Is mutation analysis of BCR ABL of any value in clinical management of CML patients?Moderator: J. GoldmanYes: A. HochhausNo: D. Marin

Should first line imatinib treatment be optimized by combination with IFN or by higher imatinib dose?Moderator: A. HochhausCombination with IFN: F. GuilhotHigher initial imatinib dose: R. Hehlmann

On the road to cure CML, does it matter to hit different pathways?Yes: F. GilesNo:


COAGULATION

Are there indications for thrombophylaxis in cancer patients during and after chemotherapy?Moderator: M.M. SamamaYes: A. FalangaNo: A. Kakkar

Is there still a role for splenectomy in ITP?Moderator: A. FalangaYes: B. GodeauNo: J. Bussel

9





HEMOGLOBINOPATHIES & PNH

Pros and cons of gene therapy in beta-thalassemiaModerator: L. LuzzattoLecture: S. Rivella

The controversies in the use of chelating drugs for the treatment of iron overloadaffect the morbidity and mortality of thalassaemia and other transfused patientsworldwideModerator: E. RachmilewitzLecture: G. Kontoghiorghes

How far one should go with iron chelation in thalassemia? Is iron deficiency indicated?Moderator: E. RachmilewitzYes: V. BerdoukasNo: M.D. Cappellini

Do the benefits of complement blockade extend to all patients with PNH clone?Yes: J. MaciejewskiNo: L. Luzzatto

10


Deadline for abstract submission:JUNE 21, 2010

We are pleased to announce a competition for the “BEST ABSTRACTS”.Six prizes of Є500 each will be awarded to the most

outstanding abstracts!


SUNDAY, SEPTEMBER 5, 2010


MPNS (MYELO PROLIFERATIVE NEOPLAMS)

Are JAK2 positive PV, ET and IM different diseases?Moderator: A. TefferiYes: W. VainchenkerNo: A.M. Vannucchi

Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferativeneoplasms?Moderator: W. VainchenkerYes: A. TefferiNo: T. Barbui


INFECTIONS

Is there a role for empirical or pre-emptive antifungal treatment in patients withhematological malignancies?Moderator: F. MenichettiYes: B. de PauwNo: A. Prentice

Is monitoring of azole concentrations of clinical value in pts with hematologicalmalignancies?Moderator: B. de PauwYes: F. MenichettiNo: P. Donnelly

10:30-12:30 PLENARY SESSION 18 Hall A

Is there a role of biologic prognostic markers in the treatment of CLL?Moderator: E. RachmilewitzFor: R. FoàAgainst: K. Rai

Are there sufficient indications for switching to new anticoagulant agents?Moderator: G. SaglioFor: M.M. SamamaAgainst: A. Falanga

Which is the best chemotherapy regimen in Hodgkin’s Lymphoma?Moderator: D. StrausABVD: A. LevisBEACOPP: V. Diehl

Is chemotherapy alone sufficient for the treatment of Hodgkin’s Lymphoma?Lecture: D. Straus

11


GENERAL INFORMATION

DATESSeptember 2-5, 2010

VENUESheraton Roma Hotel & Conference CenterViale Del Pattinaggio, 100. Rome, Italy 00144Tel: +39 06 54531Fax: +39 06 5940689

REGISTRATION FEES

Registration fees include: Participation in scientific sessions, Congress bag, program and abstractbook, all printed material of the Congress and invitation to the Welcome Reception.

ACCOMMODATIONComtecMed is the official travel agent for the 1st World Congress on Controversies inHematology (COHEM), and will be offering special reduced rates for accommodation.

LIABILITY AND INSURANCEThe Congress Secretariat and Organizers cannot accept liability for personal accidents, norloss of or damage to private property of participants, either during or directly arising fromthe 1st World Congress on Controversies in Hematology (COHEM). Participants should maketheir own arrangements with respect to health and travel insurance.

Early Registration Late Registration From Aug 26, 2010Until from June 22 until and On Site

June 21, 2010 Aug 25, 2010Participants - -Physicians and Scientists Є 540 Є 590 Є 650Residents, Nurses,Students Є 385 Є 430 Є 470Accompanying Persons Є 140

Headquarters and Administration:53 Rothschild Boulevard,PO Box 68,Tel Aviv 61000, IsraelTel: +972-3-5666166Fax: +972-3-5666177Email: [email protected]

Comtec Spain:Bailén, 95-97,pral. 1. a - 08009Barcelona, SpainTel: +34-93-2081145Fax: +34-93-4579291Email: [email protected]

Comtec China:175 Xiang Yang Road South,Shanghai 200031ChinaTel: +86-21-54660460Fax: +86-21-54660450Email: [email protected]

www.comtecmed.com/[email protected]

COHEMThe 1st World Congress on

Controversies in Hematology

Rome • Italy • September 2-5, [email protected] • www.comtecmed.com/cohem

SECOND ANNOUNCEMENT - Comtecgroup · exclusive forum for international experts to share and compare experiences, ... inaugural event of many future editions. ... Sweden A. Falanga,

Documents